Two de-risked late-stage assets; an unfolding special situation w/ an imminent catalyst; an activist board; and a discount to a recent barrage of institutional buying
Mereo Biopharma
Mereo Biopharma
Mereo Biopharma
Two de-risked late-stage assets; an unfolding special situation w/ an imminent catalyst; an activist board; and a discount to a recent barrage of institutional buying